| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/19/2009 | US20090074837 Bioresorbable Calcium-Deficient Hydroxyapatite Hydrogel Composite |
| 03/19/2009 | US20090074834 Method and system for modifying the wettability characteristics of a surface of a medical device by the application of gas cluster ion beam technology and medical devices made thereby |
| 03/19/2009 | US20090074831 LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS |
| 03/19/2009 | US20090074830 Anti-angiogenic compositions and methods of use |
| 03/19/2009 | US20090074829 Novel Heparin Alternative Material and Method for Producing the Same |
| 03/19/2009 | US20090074828 Poly(amino acid) targeting moieties |
| 03/19/2009 | US20090074824 Stable nanocapsule systems for the administration of active molecules |
| 03/19/2009 | US20090074820 Aminoarylvinyl-s-triazine compounds and uses thereof |
| 03/19/2009 | US20090074819 Polymeric nano-shells |
| 03/19/2009 | US20090074707 Shaped body and method for production of said body |
| 03/19/2009 | US20090074677 Neuroactive steroid compositions and methods of use therefor |
| 03/19/2009 | US20090074676 Inhibition of p38 MAPK For Treatment Of Obesity |
| 03/19/2009 | US20090074675 Indazoles as glucocorticoid receptor ligands |
| 03/19/2009 | US20090074674 Stabilized, biocompatible gold nanoparticles and enviro-friendly method for making same |
| 03/19/2009 | US20090074671 Drug-immobilized inorganic nanoparticle |
| 03/19/2009 | US20090074670 Hyperthermia Therapeutic Agent Delivery System |
| 03/19/2009 | US20090071477 Method And Apparatus For Vaporizing A Compound |
| 03/19/2009 | CA2699632A1 Transdermal hormone spray |
| 03/19/2009 | CA2699630A1 Transdermal, alcohol-free, pharmaceutical compositions |
| 03/19/2009 | CA2699482A1 Hybrid inducible release vehicle |
| 03/19/2009 | CA2699210A1 Titration package for neramexane and its use in the treatment of an inner ear disorder |
| 03/19/2009 | CA2699142A1 Abuse resistant drug formulation |
| 03/19/2009 | CA2699120A1 Apparatus and method for dehydrating biological materials |
| 03/19/2009 | CA2698882A1 Pharmaceutical compositions for oral use for treating patients affected by obesity |
| 03/19/2009 | CA2698573A1 Drug cores for sustained release of therapeutic agents |
| 03/19/2009 | CA2697756A1 Liquid crystal emulsion-type pharmaceutical composition containing cyclosporine, and method of treating cutaneous disease therewith |
| 03/18/2009 | EP2036921A1 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| 03/18/2009 | EP2036588A1 Acoustic telemetry apparatus for intrabody communications |
| 03/18/2009 | EP2036575A1 Pharmaceutical compositions for oral use for treating patients affected by obesity |
| 03/18/2009 | EP2036574A1 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 03/18/2009 | EP2036572A1 Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
| 03/18/2009 | EP2036559A1 Novel tape preparation |
| 03/18/2009 | EP2036558A2 Orally administrable opioid formulations having extended duration of effect |
| 03/18/2009 | EP2036549A1 Novel Composition |
| 03/18/2009 | EP2036548A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| 03/18/2009 | EP2036547A2 Treatment for Attention-Deficit Hyperactivity Disorder |
| 03/18/2009 | EP2036546A1 Psychostimulant containing pharmaceutical composition |
| 03/18/2009 | EP2036545A1 Aripiprazole tablets |
| 03/18/2009 | EP2036544A1 Dosage form of powder agglomerates |
| 03/18/2009 | EP2036543A1 Granule and preparation method thereof |
| 03/18/2009 | EP2036542A1 Epidural administration of therapeutic compounds with sustained rate of release |
| 03/18/2009 | EP2036541A1 Methods and compositions for pulmonary delivery of insulin |
| 03/18/2009 | EP2036540A2 Improved injectable dispersions of propofol |
| 03/18/2009 | EP2036539A1 Stable formulations of amylin and its analogues |
| 03/18/2009 | EP2036538A1 Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine |
| 03/18/2009 | EP2035566A2 Materials and complexes for the delivery of biologically-active material to cells |
| 03/18/2009 | EP2035476A1 Hydrophilic polyurethane compositions |
| 03/18/2009 | EP2035441A1 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| 03/18/2009 | EP2035075A1 Electronic capsule for treating gastrointestinal disease |
| 03/18/2009 | EP2035040A2 Pharmaceutical composition for administration by injection |
| 03/18/2009 | EP2035033A1 Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof |
| 03/18/2009 | EP2035031A2 Insulin composition |
| 03/18/2009 | EP2035018A1 Pathogenic attenuation via the administration of an equilibiotic compound |
| 03/18/2009 | EP2035015A2 Compositions, methods, and kits for treating dry eye |
| 03/18/2009 | EP2035010A1 Modulation of the immune system by inositol phospholipids |
| 03/18/2009 | EP2034990A2 Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists |
| 03/18/2009 | EP2034984A2 Method of treating atrophic vaginitis |
| 03/18/2009 | EP2034976A2 Delivery device having self-assembling dendritic polymers and method of use thereof |
| 03/18/2009 | EP2034975A2 Pharmaceutical compositions |
| 03/18/2009 | EP2034974A2 Lipoic acid pellets |
| 03/18/2009 | EP2034973A1 Encapsulated labile compound compositions and methods of making the same |
| 03/18/2009 | EP2034972A2 Enteric coated particles containing an active ingredient |
| 03/18/2009 | EP2034971A2 Steroid-containing sustained release intraocular implants and related methods |
| 03/18/2009 | EP2034970A2 Sustained release pharmaceutical formulation comprising phenylephrine |
| 03/18/2009 | EP2034969A2 Immediate-release tablet formulations of a thrombin receptor antagonist |
| 03/18/2009 | EP2034968A1 Galenical formulations of aliskiren and hydrochlorothiazide |
| 03/18/2009 | EP2034967A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 03/18/2009 | EP2034966A1 A stabilised composition comprising ace inhibitors |
| 03/18/2009 | EP2034965A2 Process for preparing a solid dosage form |
| 03/18/2009 | EP2034964A2 Process for producing nanoparticles by spray drying |
| 03/18/2009 | EP2034963A2 Gel-formulations of hydrophobic photosensitizers for mucosal applications |
| 03/18/2009 | EP2034962A2 Vesicular formulations containing organic acid prodrugs and process for their preparation. |
| 03/18/2009 | EP2034961A1 Solubilisate formulations |
| 03/18/2009 | EP2034960A2 Pharmaceutical compositions with biological barriers permeation enhancing properties |
| 03/18/2009 | EP2034959A2 Optimized fluorocarbon emulsions for blood substitutes and other therapeutic uses |
| 03/18/2009 | EP2034958A2 Stable aqueous suspension having palatable taste |
| 03/18/2009 | EP2034957A2 Pharmaceutical composition for oral administration |
| 03/18/2009 | EP2034956A1 Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis |
| 03/18/2009 | EP2034955A2 Collagen scaffolds, medical implants with same and methods of use |
| 03/18/2009 | EP2034954A2 Non-viral compositions and methods for transfecting gut cells in vivo |
| 03/18/2009 | EP2034953A2 Orally disintegrating layered compositions |
| 03/18/2009 | EP2034952A2 Aprepitant compositions |
| 03/18/2009 | EP2034951A2 Rehydratable pharmaceutical product |
| 03/18/2009 | EP2034950A1 Unit dose form of glufosfamide |
| 03/18/2009 | EP2034853A1 Formulations comprising a vitamin and the use thereof to make fortified feed and personal care formulations |
| 03/18/2009 | EP1948131B1 Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator |
| 03/18/2009 | EP1928407B1 Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma |
| 03/18/2009 | EP1713466B1 Antiparasitic composition containing an organic amine salt of closantel |
| 03/18/2009 | EP1530455B1 A pharmaceutical formulation and its use in the treatment of inner ear diseases |
| 03/18/2009 | EP1506031B1 Method and apparatus for vaporizing a compound |
| 03/18/2009 | EP1499300B1 Pharmaceutical formulations with improved bioavailability |
| 03/18/2009 | EP1462112B1 Remedies for dry eye and diseases associated with dry eye |
| 03/18/2009 | EP1389096B1 Delivery of opioids through an inhalation route |
| 03/18/2009 | EP1377273B1 Method for producing an isoflavone concentrate |
| 03/18/2009 | EP1353624B1 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 03/18/2009 | EP1333816B1 Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same |
| 03/18/2009 | EP1231877A4 Transdermal administration of huperzine |
| 03/18/2009 | EP1229901B1 Microfabricated devices for the delivery of molecules into a carrier fluid |
| 03/18/2009 | EP1218498B1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 03/18/2009 | EP1185288A4 Hemoactive compositions and methods for their manufacture and use |